이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Percheron Therapeutics 관리

관리 기준 확인 2/4

Percheron Therapeutics' CEO는 James Garner, Aug2023 에 임명되었습니다 의 임기는 1년 미만입니다. 는 A$ 84.00K 가치에 해당하는 회사 주식의 0.11% 직접 소유합니다. 84.00K. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 2.7 년입니다.

주요 정보

James Garner

최고 경영자

AU$33.8k

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	0.1%
경영진 평균 재임 기간	2.5yrs
이사회 평균 재임 기간	2.8yrs

최근 관리 업데이트

Recent updates

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Jun 03

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Nov 13

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

May 12

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Dec 23

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Jun 24

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Mar 11

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Nov 26

CEO

James Garner (51 yo)

less than a year

테뉴어

AU$33,804

보상

Dr. James Garner, MA, MBA, MBBS, BSC (Hons), MAICD, serves as Non-Executive Director at Percheron Therapeutics Limited (formerly known as Antisense Therapeutics Limited) since May 08, 2023 and has been its...

리더십 팀

이름	위치	테뉴어	보상	소유권
James Garner	CEO, MD & Director	less than a year	AU$33.80k	0.11% A$ 80.0k
Phillip Hains	CFO & Joint Company Secretary	17.7yrs	AU$160.28k	0.84% A$ 608.9k
Anthony Filippis	Chief Operating Officer	1.5yrs	AU$463.17k	데이터 없음
Alicia Mellors	Joint Company Secretary	3.4yrs	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

경험이 풍부한 관리: PER 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
James Garner	CEO, MD & Director	1.2yrs	AU$33.80k	0.11% A$ 80.0k
Ben Price	Independent Non-Executive Director	2.8yrs	AU$92.02k	0.11% A$ 80.0k
Charmaine Gittleson	Independent Non-Executive Chair	3.3yrs	AU$159.26k	0.081% A$ 58.7k

2.8yrs

평균 재임 기간

경험이 풍부한 이사회: PER 의 이사회는 경험(평균 재직 기간 2.7 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Percheron Therapeutics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023

Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023

Less than half of directors are independent

Antisense Therapeutics Limited Announces Retirement of Mark Diamond as Chief Executive Officer

Antisense Therapeutics Limited, Annual General Meeting, Nov 17, 2022

Antisense Therapeutics Limited Announces Appointment of Anthony Filippis as Chief Commercial Officer

Recent updates

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Consensus EPS estimates upgraded to AU$0.022 loss

Price target increased by 7.1% to AU$0.30

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023

Consensus revenue estimates increase by 71%

New minor risk - Financial data availability

New major risk - Financial position

New minor risk - Shareholder dilution

Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK

We're Not Very Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Rate

Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023

Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Antisense Therapeutics Limited Commences the Second Phase (Chronic Setting) of Its Program to Study the Effects of an Antisense Oligonucleotide (ASO) to CD49d (Mouse Equivalent of ATL1102) in a LGMDR2 Animal Model of Dysferlin Deficiency

Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMD

Antisense Therapeutics Limited Announces Clinical Trial Application Submit for ATL1102 Phase IIb DMD trial conduct in Europe

Less than half of directors are independent

Price target increased to AU$0.31

Antisense Therapeutics Limited Announces Retirement of Mark Diamond as Chief Executive Officer

Antisense Therapeutics Limited Initiates the Process with Contract Research Organisation Pharmaron

Antisense Therapeutics Limited, Annual General Meeting, Nov 17, 2022

Antisense Therapeutics Limited Announces Appointment of Anthony Filippis as Chief Commercial Officer

Price target increased to AU$0.31

Antisense Therapeutics Limited Announces Dosing Commenced in DMD Combination Therapy Study

Consensus forecasts updated

Antisense Therapeutics Limited Intends to Conduct Double-Blind, Placebo Controlled Six Month Dosing Trial of Atl1102 Followed by Six Month Open Label Phase

Full year 2022 earnings released: AU$0.009 loss per share (vs AU$0.015 loss in FY 2021)

We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely

Antisense Therapeutics Limited Announces Long COVID-19 Study Identifies Novel Blood Markers as Potential Diagnostic and Therapeutic Targets

Antisense Therapeutics Limited Announces Outcomes from Its Collaboration to Study the Neurological Aspects of Long COVID-19

Antisense Therapeutics Limited Announces ATL1102 DMD Clinical Trial Application Submitted in Europe

Antisense Therapeutics Limited Announces Results from First Study of Antisense to CD49d in Limb Girdle Muscular Dystrophy R2 Mouse Model

Antisense Therapeutics Limited Announces the Results from A First Study of Antisense to CD49d in A Limb Girdle Muscular Dystrophy R2 (LGMDR2) Mouse Model

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Price target increased to AU$0.58

Antisense Therapeutics Limited Announces Dosing Commenced in MCRI Collaboration Animal Study

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Price target increased to AU$0.60

Antisense Therapeutics Limited Announces New Data Supports ATL1102s Broader Clinical Potential

Forecast to breakeven in 2024

Price target increased to AU$0.54

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Antisense Therapeutics Limited Announces US FDA Feedback on Type C Meeting for ATL1102 in the US

Antisense Therapeutics Limited Announces Manufacture of ATL1102 clinical supplies for Phase IIb trial

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Antisense Therapeutics Limited Announces the Paediatric Investigation Plan for ATL1102 in DMD Submitted to European Medicines Agency

Antisense Therapeutics Limited Announces Executive Changes

New 90-day high: AU$0.21

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Antisense Therapeutics Limited, Annual General Meeting, Dec 18, 2020

Antisense Therapeutics Limited Announces Statistically Significant Improvement in Pul2.0 with Atl1102 Treatment in Non-Ambulant Boys with DMD Compared to A Matched Natural History Control

An unknown buyer acquired a 49% stake in Antisense Therapeutics Limited (ASX:ANP) from Opthea Limited (ASX:OPT) for AUD 0.34 million.

Antisense Therapeutics Limited Auditor Raises 'Going Concern' Doubt

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간